SPCs: first applications in France of CJEU Royalty Pharma test

In three recent rulings, the Paris Court of Appeal has highlighted the challenges pharmaceutical manufacturers can face in obtaining supplementary protection certificates (SPCs) for monoclonal antibodies on the basis of patents which disclose their function but not their structure, experts in intellectual property law have said.

Read Complete Article

MITLA is a member of the INPLP

    Subscribe for the latest
    IT Law updates

    Receive the latest IT Law updates straight to your inbox, gain access to our exclusive industry events, keep up to date with MITLA.